Vol.

No.

July 26, 2024Jul 26, 2024

DOWNLOAD THE PDF

Cover Story

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.

News Analysis White House

Kamala Harris widely expected to continue Cancer Moonshot; Conservatives present their vision in Project 2025

By McKenzie Prillaman

Letter To The Editor

Tweaking the existing systems is not the answer to drug shortages

Clinical Trials & Tribulations

Better oncology drug management could lead to improved outcomes, lower costs

By Matt Ingram

Free In the Archives

Before the Olympics were smoke-free, tobacco brand deals ran rampant

In Brief

Jonathan Gerber named chief clinical officer of NYU Langone Health’s Perlmutter Cancer Center

Newman, Salami named associate directors at UMich Rogel Cancer Center

Sanjay Reddy named division chief of surgical oncology at Fox Chase

Michelle Pedersen joins Fox Chase as hospitalist and assistant professor in the Division of Hospital Medicine

Kristi Hendriks joins Lymphoma Research Foundation board of directors

UCLA researchers awarded $4M to advance immunotherapy treatment for pancreatic cancer

Israel’s only cancer hospital opens Adolescent & Young Adult Cancer Clinic

Clinical Roundup

Bintrafusp alfa shows tumor response rate for patients with recurrent or metastatic cervical cancer

Socioeconomic status affects survival of children with cancer

Neighborhood violence may influence tumor biology, worsening lung cancer outcomes

Novel liquid biopsy methodology can track evolution of metastatic prostate cancer

CD5 deletion enhances the antitumor activity of adoptive T-cell therapies

New payment code and Medicare payment implemented for AI cancer imaging device

Thermo Fisher, NCI collaborate to advance myeloid cancer research, treatment utilizing next-gen sequencing technology

Drugs & Targets

FDA accepts Telix’s NDA for prostate cancer imaging agent

FDA clears IND for Zymeworks’ antibody drug conjugate ZW191

EMA validates application for BMS’s Opdivo + Yervoy for unresectable or advanced HCC

EMA accepts MAA for GSK’s Blenrep combinations for R/R MM

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 50 | Issue 34 - September 13, 2024